These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 18559790

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib.
    Tamaskar I, Bukowski R, Elson P, Ioachimescu AG, Wood L, Dreicer R, Mekhail T, Garcia J, Rini BI.
    Ann Oncol; 2008 Feb; 19(2):265-8. PubMed ID: 17962201
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients.
    Raspollini MR.
    Curr Oncol Rep; 2007 Sep; 9(5):331. PubMed ID: 17706159
    [No Abstract] [Full Text] [Related]

  • 45. Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb.
    Raymond AK, Puri PK, Selim MA, Tyler DS, Nelson KC.
    Arch Dermatol; 2010 Dec; 146(12):1438-9. PubMed ID: 21173337
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
    Alexandrescu DT, McClure R, Farzanmehr H, Dasanu CA.
    J Clin Oncol; 2008 Aug 20; 26(24):4047-8. PubMed ID: 18711201
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
    Kondo T.
    Nihon Jinzo Gakkai Shi; 2012 Aug 20; 54(5):574-80. PubMed ID: 22991835
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Sorafenib rechalenge in metastatic renal cell carcinoma.
    Porta C, Paglino C, Imarisio I.
    BJU Int; 2012 Sep 20; 110(6 Pt B):E235. PubMed ID: 22332769
    [No Abstract] [Full Text] [Related]

  • 56. Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism.
    Bellini E, Pia A, Brizzi MP, Tampellini M, Torta M, Terzolo M, Dogliotti L, Berruti A.
    Ann Oncol; 2011 Apr 20; 22(4):988-990. PubMed ID: 21321087
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
    Chu D, Lacouture ME, Fillos T, Wu S.
    Acta Oncol; 2008 Apr 20; 47(2):176-86. PubMed ID: 18210295
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.